ObjectivesVarious genomic alterations and genomic signatures, including ERBB2 amplification, mutations in PIK3CA, AKT1, and ESR1, and tumor mutational burden (TMB), have become important biomarkers fo
Table S4. In silico analysis of TMB association or predictive value for immunotherapy response. These analyses were performed on panel-based TMB values simulated in silico using a subset of WES which
Additional file 10: Table S4. a: this table gives the estimated tumor mutational burden (eTMB, the number of somatic mutations) and cell fractions from bulk expression matrix for 11 paired CccRCC samp
Additional file 2: Fig. S1. TMB score variation according to DNA sample quality and according to sample type (FFPE or frozen) in 10 sample pairs. FFPE = Formalin-Fixed Paraffin-Embedded; TMB = Tumor M
Objective: To explore the use and safety of penpulimab in real world. Methods: Totally 13 inpatients using penpulimab were observed from April to December 2022 in a cancer hospital. The data of patien
